Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
- 25 April 2005
- journal article
- research article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 20 (5) , 459-464
- https://doi.org/10.1002/gps.1341
Abstract
Introduction Behavioural symptoms are common in moderate to severe Alzheimer's disease (AD). We have analysed the databases of two randomised studies with regard to the effects of memantine treatment on behavioural symptoms, measured using the 12‐item version of the Neuropsychiatric Inventory (NPI). Subjects The monotherapy study (memantine only) reported by Reisberg et al. (2003) involved 252 patients with baseline MMSE total score of between 3 and 14, whereas the combination study (memantine and donepezil) reported by Tariot et al. (2004) comprised 404 patients with MMSE scores of between 5 and 14. In both studies, patients received 10 mg memantine b.i.d. or matching placebo, and lived in the community. Methods For both studies NPI total and individual domains scores were analysed in the ITT population. For the monotherapy study a dichotomised analysis was performed separately for patients who had behavioural symptoms at baseline and for those without pre‐existing symptoms. Furthermore, a factor analysis was used to identify any behavioural clusters within the patient population. Results In both studies, the change in NPI total scores at endpoint was consistently in favour of memantine treatment, reaching statistical significance in the combination study (p = 0.002). Memantine treatment showed a significant beneficial effect in comparison to placebo treatment in the NPI agitation/aggression domain in both studies (p = 0.008; p = 0.001). The dichotomised analysis of the monotherapy study showed that there was significantly less agitation/aggression emerging in the memantine‐treated group compared to placebo (p = 0.003). Factor analysis showed that hyperactivity accounted for 27% of the data variance. Conclusions Memantine has a beneficial effect on the behavioural symptoms of patients with moderate to severe AD, with the most pronounced effect on agitation/aggression. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s DiseaseAmerican Journal of Psychiatry, 2004
- Pharmacologic Management of Agitation in Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2003
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- Behavioral Problems in Dementia: A Factor Analysis of the Neuropsychiatric InventoryDementia and Geriatric Cognitive Disorders, 2003
- Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer’s DiseaseInternational Psychogeriatrics, 2002
- A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology, 2001
- The Neuropsychiatric InventoryNeurology, 1997
- The Neuropsychiatric InventoryNeurology, 1994
- Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)Neuropharmacology, 1993
- Institutionalization of Alzheimer's Disease PatientsHome Health Care Services Quarterly, 1987